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Splice Variant 1 (SV-1) of growth hormone-releasing hormone (GHRH) receptor, found in a wide range of human cancers and
established human cancer cell lines, is a functional receptor with ligand-dependent and independent activity. In the present study, we
demonstrated by western blots the presence of the SV1 of GHRH receptor and the production of GHRH in MDA-MB-468,
MDA-MB-435S and T47D human breast cancer cell lines, LNCaP prostate cancer cell line as well as in NCI H838 non-small cell lung
carcinoma. We have also shown that GHRH produced in the conditioned media of these cell lines is biologically active. We then
inhibited the intrinsic production of GHRH in these cancer cell lines using si-RNA, specially designed for human GHRH. The knocking
down of the GHRH gene expression suppressed the proliferation of T47D, MDA-MB-435S, MDA-MB-468 breast cancer, LNCaP
prostate cancer and NCI H838 non-SCLC cell lines in vitro. However, the replacement of the knocked down GHRH expression by
exogenous GHRH (1–29)NH2 re-established the proliferation of the silenced cancer cell lines. Furthermore, the proliferation rate of
untransfected cancer cell lines could be stimulated by GHRH (1–29)NH2 and inhibited by GHRH antagonists MZ-5-156, MZ-4-71
and JMR-132. These results extend previous findings on the critical function of GHRH in tumorigenesis and support the role of
GHRH as a tumour growth factor.
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Dysfunction of cell differentiation and cell cycle regulation define
and promote carcinogenesis. Growth hormone-releasing hormone
(GHRH) was first isolated from human pancreatic tumours and
only subsequently identified in human and animal hypothalami
(reviewed in Schally and Varga, 2006). The full intrinsic biological
activity of GHRH is retained by the NH2-terminal 29 amino acid
sequence. Growth hormone-releasing hormone is secreted by the
hypothalamus and upon binding to the specific GHRH-Receptors
(GHRH-R) on somatotrophs regulates the release of Growth
Hormone (GH) from the anterior pituitary gland. In turn, GH
stimulates the production of insulin-like growth factor-I (IGF-I),
which functions as a cell cycle stimulator (Macaulay, 1992; Westley
and May, 1995).
Growth hormone-releasing hormone-receptors (GHRH-R) is a
class II G protein-coupled receptor and contains seven transmem-
brane domains (Mayo, 1992). Growth hormone-releasing hormone-
receptor is homologous with the receptors for the vasoactive
intestinal peptide (VIP), the pituitary adenyl cyclase activating
polypeptide and calcitonin (Gaylinn et al, 1993). Recently, peptide
receptors that mediate the effects of GHRH and its antagonists on
tumours were identified. The isolation and sequencing of cDNAs
which correspond to the tumoral GHRH receptor mRNA revealed
that they are splice variants (SVs) of the pituitary GHRH receptors
(pGHRH-R) (Rekasi et al, 2000).
Splice variant 1 of GHRH receptor is a functional receptor,
which differs from the pGHRH-R only in the N-terminal
extracellular domains. The first 89 amino acids of the pGHRH-R
are replaced in SV-1 receptor by a different 25-amino acid
sequence (reviewed in Schally and Varga, 2006). Some tumours
also express pituitary type of GHRH receptor (Havt et al, 2005;
Christodoulou et al, 2006). Besides its ligand-dependent activity, a
ligand-independent activity of SV1 has also been demonstrated
(Kiaris et al, 2003). A recent study showed the stimulation and
proliferation of MCF-7 breast cancer cells after the transfection of
SV1 (Barabutis et al, 2007). The expression of mRNA for GHRH
and the presence of biologically or immunologically active GHRH
were demonstrated in several established cancer cell lines and
human tumours. Collectively, those data suggest that GHRH may
function as a growth factor among a large class of mitogens
involved in tumorigenesis. In an endeavour to develop new
methods for cancer treatment, we developed the antagonists of
GHRH (reviewed in Schally and Varga, 2006).
Growth hormone-releasing hormone antagonists suppress the
in vivo growth of various experimental cancers such as prostatic
(Zarandi et al, 2006; Stangelberger et al, 2007), mammary
(Buchholz et al, 2007), ovarian (Chatzistamou et al, 2001), renal
cell carcinomas (Halmos et al, 2000), small cell lung carcinomas
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s(Hohla et al, 2006), pancreatic and colorectal carcinomas
(Szepeshazi et al, 2000; Busto et al, 2002), endometrial
(Engel et al, 2005), osteogenic sarcomas (Braczkowski et al,
2002) as well as malignant glioblastomas (Jaeger et al, 2005).
The inhibitory effect of antagonistic analogues of GHRH is
exerted in part by endocrine mechanisms through the suppression
of GHRH-evoked GH release from the pituitary, which, in turn
results in the reduction of hepatic production of IGF-I and a
decrease in the serum IGF-I levels. The anti-tumour effects of
GHRH antagonists can be also mediated through direct mechanisms.
One of these mechanisms is based upon the inhibition of the
secretion of autocrine/paracrine IGF-I or IGF-II from the tumours,
while probably the most important pathway involves the blockade
of action of autocrine GHRH in tumours. The antitumour activity
of our GHRH antagonists is especially important oncologically
because of the wide expression of the intrinsic GHRH, pGHRH-R
and SVs of GHRH-R in various cancers.
In the present study, we evaluated by western blot the
expression of the SV-1 of GHRH-R and its GHRH ligand in
human breast cancer (MDA-MB-468, MDA-MB-435S, T47D),
prostate cancer (LNCaP) and non-SCLC (NCI H838) cell lines.
We detected the GHRH produced in the conditioned medium
of these cell lines. To further elucidate the role of GHRH in
carcinogenesis, we knocked down the gene expression of GHRH.
In addition, we examined the effect of GHRH and GHRH
antagonists MZ-4-71, MZ-5-156 and JMR-132 at two dose levels
on the proliferation rate of the cited cancer cell lines. Our results
demonstrate the critical function of GHRH and its receptors in
tumorigenesis.
MATERIALS AND METHODS
Peptides and chemicals
Growth hormone-releasing hormone antagonists JMR-132 [PhAc
0,
DArg
2, Phe (4-C)
6, Ala
8, Har
9, Tyr (Me)
10, His
11, Abu
15, His
20,
Nle
27, D-Arg
28, Har
29] human GHRH (1–29)NH2, MZ-5-156
[PhAc-Tyr
1, D-Arg
2, Phe (4-CI)
6, Abu
15, Nle
27 hGHRH
(1–28)Agm and MZ-4-71 [Ibu-Tyr
1, D-Arg
2, Phe (4-CI)
6, Abu
15,
NIe
27] hGHRH (1–28) Agm, where Abu is a-aminobutyric acid,
Agm is agmatine, Har is homoarginine, Nle is norleucine, PhAc is
phenylacetyl and Tyr(Me) is O-methyltyrosine were synthesized in
our laboratory by solid phase methods (1,19). Growth hormone-
releasing hormone (1–29)NH2 and GHRH antagonists were
dissolved in 0.1% DMSO and diluted with incubation media.
Cell culture
The cell lines (LNCaP, MCF-7, MDA-MB-468, MDA-MB-435s,
T47D, and NCI-H838) were obtained from American Type Culture
Collection (Manassas, VA, USA) and cultured at 371Ci na
humidified 95% air/5% CO2 atmosphere. Breast cancer cell lines
MCF-7, MDA-MB-468, MDA-MB-435s and T47D were cultured in
DMEM supplemented with antibiotics/antimycotics and 10% FBS.
Prostate cancer cell line (LNCaP) and non SCLC cell line NCI
H838 were cultured in RPMI-1640 supplemented with antibiotics/
antimycotics and 10% fetal bovine serum (FBS). The culture media
were purchased from GIBCO (Carlsbad, CA).
Protein isolation and western blot assay
The expression of GHRH and SV1 receptor was assessed by
western blot in T47D, MDA-MB-435s, MDA-MB-468 breast cancer
cell lines, LNCaP prostate cancer line and NCI H838 non-SCLC
line. MCF-7 breast cancer cell line which does not produce either
GHRH or SV1 receptor was used as negative control (Barabutis
et al, 2007). The proteins were isolated from the cells using
CelyticM Lysis Reagent (Sigma, St Louis, MO, USA) and the
concentration of the isolated proteins was determined by
Quickstart Bradford Protein Assay (Bio-Rad, Hercules, CA, USA)
according to manufacturer’s instructions. Protein matched sam-
ples (15mg per lane) were separated by electrophoresis 12.5 or
8–16% sodium dodecyl sulphate (SDS–PAGE Tris-HCL precast
gels (Bio-Rad, Hercules, CA, USA). Electroblotting was used to
transfer the proteins onto nitrocellulose membranes (Biorad,
Hercules, CA, USA). The membranes were incubated for 3h at
room temperature in 5% non fat dry milk in phosphate-buffered
saline (PBS) – 0.1% (v/v) Tween 20. The blots were then incubated
at 41C overnight with an affinity purified goat polyclonal antibody
against a peptide mapping near the N terminus of GHRH of human
origin (1:425) (cat no. 10280, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and with rabbit antiserum to SV1 (1:2000) raised in our
laboratory (Toller et al, 2004). The antiserum batch number for SV1
was JH 2317/5. The signal for the immunoreactive proteins was
developed with peroxidase-conjugated secondary antibodies (Santa
Cruz and Cell Signalling, Danvers, MA, USA) and visualised by
exposure to chemiluminescence substrate (Amersham Biotechnologies,
Piscataway, NJ, USA). The b-actin signal (1:1000, Santa Cruz) was
used as control.
Quantitative analysis of the immunoblot assay
The protein bands signals were quantified by Adobe Photoshop
and normalised to b-actin signal. The intensity of the bands was
equal to their mean value multiplied by their pixel value (absolute
intensity). Relative intensity (RI) of each band is calculated by
dividing its absolute intensity by the absolute intensity of the
control band (b-actin). The percentage efficiency of the knocking
down of the GHRH gene expression was calculated as {(R.I of
the Pre-pro GHRH band of untransfected cells – RI of the pre-pro
GHRH band of transfected cells)/RI of the Pre-pro GHRH band of
untransfected cells}  100.
Radioimmunoassay of GHRH
Tumour cells (3 10
5cells) were seeded in 48-well petri dishes and
allowed to attach for 24h when the media were replaced by serum-
free medium (SFM). Aliquots of 0.1ml medium from MCF-7,
T47D, MDA-MB-435s, MDA-MB-468 breast cancer cell lines, LNCaP
prostate cancer cell line and NCI H838 non-SCLC cell line growing for
0, 24, 48 and 72h were assayed for GHRH immunoreactivity.
Growth hormone-releasing hormone was measured by using
([
125I]-Tyr)-GHRH-]) (human) (Bachem, cat no. H-5028) as the
labelled peptide and a rabbit antibody against GHRH (1–44)NH2
(Bachem, cat no. S 2027). This antibody crossreacts 100% with
human GHRH (1–44)NH2 and 30% with human GHRH (1–29)NH2.
Growth hormone-releasing hormone (1–44)NH2 (Bachem, cat no.
H-3695) was used as a standard. The range was 1–128pg per tube.
Transfection
Small interfering (si) RNA designed specially for the inhibition of
the human GHRH was used to knock down the GHRH gene
expression of the T47D, MDA-MB-435s, MDA-MB-468 breast
cancer cell lines, LNCaP prostate cancer cell line and NCI H838
non-SCLC cell line. A pool of three oligonucleotides especially
designed for the inhibition of the human GHRH (sc39519, Santa
Cruz Biotechnology) and cationic liposomes (Lipofectamine,
Invitrogen, Carlsbad, CA, USA) were used to knock down the
gene expression of the GHRH. The sequence of the sense strand (a)
was GGUAUGCAGAUGCCAUCUUTT and the mRNA location is
92. The sequence of the sense strand (b) was CCAGUUAAUCCUCU
CAUUUTT and its mRNA location is 376. The sequence of the
sense strand (c) was CCAGUUAAUCCUCUCAUUUTT and its
mRNA location is 434. RNA that does not lead to any specific
degradation of any known cellular mRNA (control siRNA, sc37007,
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sSanta Cruz Biotechnology) was used as control. The sequence of the
sense strand was UUCUCCGAACGUGUCACGU. One day before
the transfection, the cells were plated in six-well plates in 2ml of
growth media without antibiotics to be 40% confluent on the day
of transfection. For the transfection 40–60nM siRNA was diluted
in 0.25ml Opti-MEM I Reduced Serum Medium (Invitrogen,
Carlsbad, CA, USA) without serum and 5ml lipofectamine 2000
were diluted in an equal volume of Opti-MEM I. After incubation
for 5min at room temperature, the diluted oligomers were
combined with the lipofectamine 2000 and incubated for 30min
also in room temperature. The oligomer-lipofectamine complexes
were added to each well, which contained 2ml of medium without
antibiotics. The medium was changed 8h after transfection. The
cells were incubated at 371C in an atmosphere of 5% CO2 and 95%
air for 48–72h after transfection and then assayed by western blot
for gene knockdown.
Cell proliferation rate assay
The rate of the cell proliferation was calculated by seeding 10000
cells in six-well plates and after an incubation for 4 days counting
them under light microscope using the trypan blue assay.
Statistical analysis
These data are expressed as the mean±s.e.m. Statistical evaluation
of the results was performed by the Student’s t-test (two-tailed).
P-values shown are against the control group.
RESULTS
Expression of growth hormone releasing hormone and
splice variant 1 of the GHRH receptor in breast and
prostate cancer and non-SCLC cell lines
A band of 45KDa which reflects the production of pre-pro GHRH
(Othman et al, 2001) was detected in all the cancer cell lines
examined. The results are shown in Figure 1. Pre-pro GHRH
protein expression was the highest in T47D (R.I:0.464), followed by
MDA-MB-435s (R.I:0.449), NCI H838 (R.I:0.437), MDA-MB-468
(R.I:0.312) and LNCaP (R.I:0.193). A band at 39.5KDa which is
consistent with the size of the SV1 receptor (Havt et al, 2005) was
also detected in all the cancer cell lines examined. The results are
shown in Figure 2. The levels of the SV1 GHRH-R protein were the
highest in T47D (R.I:0.696), followed by NCI H838 (R.I:0.376),
MDA-MB-435s (R.I:0.316), LNCaP (R.I:0.169), MDA-MB-468
(R.I:0.160).
Detection of the secretion of growth hormone-releasing
hormone in the conditioned medium of the cancer cell
lines by radioimmunoassay
The concentration of the GHRH in samples from culture medium
was measured by RIA. Significant amounts of GHRH were detected
in the medium from T47D (1.518, 2.083, 0.266ngml
 1), NCI
H838(0.303, 0.442, 0.689ngml
 1), MDA-MB-435s (0.675, 1.036,
1.442ngml
 1), LNCaP(0.202, 0.218, 0.208ngml
 1), and MDA-MB-
46ngml
 1 (0.637, 0.816, 0.649) cell lines after 24, 48 and 72h
respectively as shown in Table 1. Growth hormone-releasing hormone
was not detected either in the cultured medium without cells or in the
conditioned medium of the MCF7 breast cancer cell line.
Inhibition of the GHRH gene expression in breast, prostate
and non-SLCL cancer cell lines and its effect on
proliferation
The effective inhibition of the GHRH gene expression was
confirmed by western blot. The results are seen in Figure 3. The
GHRH expression in the transfected NCI H838, LNCaP, T47D cell
lines was suppressed by 85, 85 and 92% respectively. The
decreased proliferation rate of the MDA-MB-468 and MDA-MB-
435s cell lines did not allow us to isolate protein from those cells
during early cell passages. Since the silencing of the gene
expression for GHRH lasts only for limited cell passages, the
western blots of the proteins obtained in late cell passages show
Table 1 Production of GHRH in culture medium from human breast cancer (MCF-7, MDA-MB-468, MDA-MB-435S, T47D) prostate cancer (LNCaP)
and non-small cell lung carcinoma (NCI H838) cell lines
GHRH (ngml
 1 medium) produced by CANCER CELL LINES
Time (hour) MCF-7 T47D MDA-MB-468 MDA-MB-435s LNCaP NCI H838
0N D N D N D N D N D N D
24 ND 1.518 0.637 0.675 0.202 0.303
48 ND 2.083 0.816 1.036 0.218 0.442
72 ND 0.266 0.649 1.442 0.208 0.689
ND¼not detectable. Aliquots of medium were subjected to RIA for the detection of GHRH at the indicated periods of time.
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Figure 1 Western blot analysis of protein expression of GHRH in breast
cancer (MCF-7, MDA-MB-468, MDA-MB-435s, T47D), lung cancer
(NCI-H838) and prostate cancer (LNCaP) cell lines. MCF-7 breast cancer
cell line was used as negative control. Signal intensity of the 45kDa
precursor GHRH protein is indicated by the symbol þ. Protein levels were
normalised to b-actin signal.
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Figure 2 Western blot analysis of expression of SV1 in breast cancer
(MCF-7, MDA-MB-468, MDA-MB-435s, T47D), lung cancer (NCI-H838)
and prostate cancer (LNCaP) cell lines. MCF-7 breast cancer cell line was
used as negative control. Signal intensity of GHRH protein is indicated by
the symbol þ. Protein levels were normalised to b-actin signal.
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sthat the silencing of the GHRH gene expression was less effective
for the two breast cancer cell lines in these passages (28 and 64%
respectively). After the knocking down of GHRH expression, the
proliferation rate of the T47D, MDA-MB-435s, MDA-MB-468,
LNCaP, NCI H838 human cancer cell lines was decreased by 28.3,
85.9, 85.1, 51.8 and 48.4% respectively (Figure 4). The transfection
of siRNA for GHRH did not influence the proliferation rate of
MCF-7 cells. We also used control siRNA, which contains a
scrambled sequence that does not lead to the specific degradation
of any known cellular mRNA for transfection of all cell lines. No
changes in the proliferation rate and no toxic effect were found in
any cell lines.
Effect of GHRH(1–29)NH2 on the proliferation of the
knocked down cancer cell lines in vitro
When knocked down T47D, MDA-MB-486, MDA-MB-435s breast,
LNCaP prostate and NCIH-838 lung cancer cell lines were exposed
to 0.1mM. Growth hormone-releasing hormone (1–29)NH2 the
proliferation rate of the cells was strongly stimulated by 16, 132, 87,
97, 119% respectively. The increase on the proliferation rate in
response to 1mM GHRH was even greater, being 32, 143, 112, 134,
140% respectively. The GHRH did not affect the proliferation rate
of MCF-7 breast cancer cell line, which was also transfected with
siRNA for GHRH. The results are shown in Figure 5.
Effect of GHRH(1–29)NH2 and GHRH antagonists on the
proliferation of cancer cell lines in vitro
T47D, MDA-MB-486, MDA-MB-435s breast, LNCaP prostate and
NCIH-838 lung cancer cell lines cultured in vitro were exposed to
two concentrations of GHRH(1–29)NH2 and GHRH antagonists
MZ-5-156, JMR-132 and MZ-4-71. At the dose of 1mM GHRH
(1–29)NH2 did not appreciably influence the proliferation rate of
the cells, producing a change only of 1–5%. However GHRH
(1–29)NH2 at 0.1mM concentration stimulated of the proliferation
rate of the T47D, MDA-MB-468, MDA-MB-435s, LNCaP and NCI
H838 cells by 15, 17, 14, 14, 16% respectively. The proliferation of
MCF-7 cells (negative control) was not affected by GHRH at 0.1
and 1mM concentrations. The results are shown in Figure 6.
Growth hormone-releasing hormone antagonist MZ-4-71 at the
dose of 0.1mM decreased the proliferation of T47D, MDA-MB-468,
MDA-MB-435s, LNCaP and NCI H838 cancer cell lines by 37, 29,
32, 29, 28% respectively. The results are presented in Figure 7. At
the dose of 1mM MZ-4-71 produced a somewhat greater inhibition
of proliferation of T47D, MDA-MB-468, MDA-MB-435s, LNCaP
and NCI H838, the decreases being 39, 35, 36, 35 and 33%
respectively. MZ-4-71 did not affect the proliferation of MCF-7
cells (negative control) (Figure 7).
Similar inhibitory effects on proliferation were obtained with the
other two antagonists. Thus GHRH antagonist MZ-5-156 at doses
of 0.1 and 1mM reduced the proliferation of T47D, MDA-MB-468,
MDA-MB-435s, LNCaP and NCI H838 cancer cell lines by 30–35,
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Figure 3 Western blot analysis of GHRH in cancer cell lines before and
after the inhibition of the GHRH gene expression. The knocked down cells
are marked as si. MCF-7 breast cancer cell line was used as negative
control. Protein levels were normalised to b-actin signal. (A) The detection
of the GHRH protein expression in breast (T47D), lung (NCI-H838) and
prostate cancer (LNCaP) cell lines. (B) The detection of the GHRH protein
expression in breast cancer (MDA-MB-468, MDA-MB-435s) cell lines.
NCIH-838 cancer cell line was used as positive control. Signal intensity
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100
80
60
MCF7 
NS
T47D
MDA-MB-435S
MDA-MB-468
LNCaP
NCIH838
∗∗
∗∗∗
∗
∗∗
∗∗
%
 
d
e
c
r
e
a
s
e
 
i
n
 
t
h
e
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
r
a
t
e
 
o
f
 
t
h
e
 
c
a
n
c
e
r
 
c
e
l
l
 
l
i
n
e
s
 
a
f
t
e
r
 
i
n
h
i
b
i
t
i
o
n
 
o
f
 
e
x
p
r
e
s
s
i
o
n
 
 
o
f
 
t
h
e
 
G
H
R
H
40
20
0
Figure 4 Graphic presentation of the decrease in the proliferation rate
of the MBA-MB-468, MDA-MB-435s T47D, LNCaP and NCI H838 after
the knocking down of the expression of the ectopic GHRH. MCF-7 breast
cancer cell line was used as control. Vertical bars represent s.e.m. Data are
representative of one experiment in triplicate in each case. Percentage
decrease and signalling are expressed vs corresponding untreated cells.
*Po0.05, **Po0.005, ***Po0.001.
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Figure 5 Effect of GHRH(1–29)NH2 at 0.1 and 1mM concentrations on
the proliferation rate of the knocked down siMDA-MB-468, siMDA-MB-
435s and siT47D breast, siNCI-H838 lung cancer and siLNCaP prostate
cancer cell lines. MCF-7 breast cancer cell line was used as control. Data are
representative of one experiment in triplicate. Percentage increase and
significance is expressed vs knocked down cells cultured in the absence of
GHRH. *Po0.05, **Po0.005, ***Po0.001.
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s28–34, 33–40, 30–37, and 30–36% respectively. Higher doses of
the GHRH antagonist again caused a greater inhibition, indicated
by the second set of numbers. The results are illustrated in
Figure 8.
The proliferation of T47Ds, MDA-MB-468, MDA-MB-435,
LNCaP and NCI H838 cancer cell line was also inhibited by
31–37%, 26–31%, 31–38%, 34–41%, 37–42% respectively after
exposure to GHRH antagonist JMR-132 at doses of 0.1 and 1mM.
Higher doses of JMR-132 produced a greater inhibition, indicated
by the second set of numbers. The results are shown in Figure 9.
DISCUSSION
Growth hormone-releasing hormone and the major SV1 of the full
length GHRH receptor are expressed in surgical specimens of
diverse human cancers as well as in a various human cancer cell
lines (reviewed in Schally and Varga, 2006). These findings led to
the concept that GHRH may function as an autocrine growth factor
in many human malignancies.
The precise role of the production of GHRH in the process of
tumorigenesis and tumour progression has not been investigated
previously. One way to elucidate the role of GHRH in the
pathogenesis of cancer is to inhibit its gene expression. In the
present study, we first examined the expression of pre-pro GHRH
by western blot in human cancer cell lines. The band that reflects
the production of the pre-pro GHRH appeared to have a molecular
size of 45kDa on the blots. The facts that this band disappeared in
the knocked down cells and could not be detected in the negative
control (MCF-7), together with the stimulation of the knocked
down cells by exogenous GHRH, indicate that this band represents
a precursor of GHRH (Othman et al, 2001). We also tried to
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Figure 6 Effect of GHRH(1–29)NH2 at concentrations of 0.1 and 1mM
on the proliferation rate of MCF-7, MDA-MB-468, MDA-MB-435s and
T47D breast, lung (NCI-H838) and prostate (LNCaP) cancer cell lines.
Vertical bars represent s.e.m. Data are representative of one experiment in
triplicate. Percentage increase and significance are expressed vs cells
cultured in the absence of GHRH. *Po0.05, **Po0.005.
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Figure 7 Effect of GHRH antagonist MZ-4-71 at two concentrations
(0.1, 1mM) on the proliferation rate of MCF-7, MDA-MB-468, MDA-MB-
435s and T47D breast, lung (NCI-H838) and prostate (LNCaP) cancer cell
lines. Vertical bars represent s.e.m. *Po0.001. Data are representative of
one experiment in triplicate. Percentage increase and significance are
expressed vs cells cultured in the absence of the antagonist. *Po0.05,
**Po0.005.
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Figure 8 Effect of GHRH antagonist MZ-5-156 at two concentrations
(0.1, 1mM) on the proliferation rate of MCF-7, MDA-MB-468, MDA-MB-
435s and T47D breast, lung (NCI-H838) and prostate (LNCaP) cancer cell
lines. Vertical bars represent s.e.m.*Po0.001. Data are representative of
one experiment in triplicate % increase and significance are expressed vs
cells cultured in the absence of the antagonist. *Po0.05, **Po0.005.
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Figure 9 Effect of GHRH antagonist JMR-132 at two concentrations
(0.1, 1mM) on the proliferation rate of MCF-7, MDA-MB-468, MDA-MB-
435s and T47D breast, lung (NCI-H838) and prostate (LNCaP) cancer cell
lines. Vertical bars represent s.e.m. *Po0.001. Data are representative of
one experiment in triplicate. Percentage increase and significance are
expressed vs cells cultured in the absence of the antagonist. *Po0.05,
**Po0.005, ***Po0.001.
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western blots for synthetic GHRH (1–44) NH2, but no corresponding
signal was detected. Biologically active GHRH was detected by
RIA in the conditioned medium of all the cancer cell lines, except
for MCF-7.
We then evaluated the expression of the SV1 of GHRH receptor
by western blot. The expression of the GHRH and its receptor SV1
in the breast, prostate and non-SCLC cancer cell lines examined
suggested the presence of a stimulatory loop in those cells based on
GHRH and its receptors. This raised the issue of establishing the
role of GHRH in these cancer lines.
Small interfering siRNA for GHRH was used to elucidate the
exact function of GHRH. The siRNA for GHRH is a pool of
specially designed RNAs for knocking down the expression of
human GHRH. After the transfection of the siRNA for GHRH, the
proliferation rate of the MDA-MB-468 and MDA-MB-435s cancer
lines was dramatically decreased by 85.1 and 85.9% respectively.
The decreased proliferation, in combination with the fact that the
silencing of the gene expression for GHRH lasts only for limited
cell passages, did not allow us to isolate protein from these cells for
western blot analysis during early cell passages. The isolation of
the proteins obtained in late cell passages showed that the silencing
of the GHRH gene expression was less effective in these passages.
In the case of the T47D cells the proliferation rate was decreased
by 28.3%. The T47D cell line has the highest expression of SV-1 of
the GHRH receptor with its ligand-dependent and independent
activity. The inhibition of the gene expression for GHRH in T47D
breast cancer cell line did not have the potent antiproliferative
effect found in the other two breast cancer cell lines (MDA-MB-468
and MDA-MB-435S), possibly because the ligand independent
activity of the SV1 continued to enhance the proliferation rate of
the T47D cells (Kiaris et al, 2003; Barabutis et al, 2007).
Prostate cancer cell line LNCaP and non-SCLC cell line NCI
H838 showed decreases in proliferation rates of 51.8 and 48.4%
respectively after the inhibition of the GHRH gene expression.
Both these cancer cell lines express SV-1 and because of its
ligand-independent activity their proliferation rate continued to be
stimulated in the absence of the intrinsic production of the GHRH.
The possible presence of GHRH and other related peptides such
as VIP in the media of the cells that were tested cannot be
excluded. Thus GHRH could keep acting as a growth factor and the
proliferation rate of all the cancer cell lines that were assayed may
not reflect the conditions of a total absence of GHRH.
MCF-7 breast cancer cells were also transfected with siRNA for
knocking down the GHRH gene. This was done to test for any
possible toxic effects, which could be related to the presence of the
siRNA because MCF-7 line does not produce GHRH, its behaviour
after the transfection had to remain the same. The transfection of
the siRNA for GHRH did not influence the proliferation rate of the
MCF-7 cells. Consequently the decreased proliferation rate of the
breast, prostate and non-SCLC after the transfection was not due
to toxic effects. The transfection of control siRNA did not lead to
any changes in the proliferation of these cells.
In addition, we exposed the knocked down MDA-MB-468,
MDA-MB-435s, T47D, LNCaP and NCI-H838 cancer cell lines to
two different concentrations of GHRH (1–29)NH2. The prolifera-
tion rate of the cells was strongly stimulated by the addition of
exogenous GHRH, not only at the concentration of 0.1mM but also
at a concentration of 1mM. The silenced cancer cell lines, lacking
intrinsic GHRH, were still able to respond to exogenous GHRH,
confirming the absence of possible toxic effects related to the
transfections. MCF7 cells transfected with siRNA for GHRH were
also exposed to GHRH. The proliferation rate of the transfected
MCF7 cells was not influenced by the addition of the exogenous
GHRH.
We also investigated the effect of GHRH and GHRH antagonists
at two concentrations in MCF-7, MDA-MB-468, T47D, MDA-MB-
435s, LNCaP and NCI H838 cancer cell lines. The proliferation rate
of the MCF-7 breast cancer cell line was not influenced by the
presence of the GHRH or its antagonists, since MCF-7 does not
express specific receptors for GHRH. At the dose of 0.1mM GHRH
stimulated the proliferation rate of the cancer cell lines by
15–17%. However, at a dose of 1mM GHRH did not influence
significantly the proliferation rate of cell lines. Thus, because of the
possible presence of GHRH or other related peptides in the
medium, as well as of GHRH secreted by the cells, it is likely that
the corresponding signalling pathways were saturated after
exposure to 1mM GHRH.
These breast, lung and prostate cancer cell lines were also
exposed in vitro to two concentrations of GHRH antagonists
MZ-4-71, MZ-5-156 and JMR-132. At concentrations of 0.1 and
1mM, the proliferation rate of these cells was decreased by 26–37%
and 31–42% respectively.
The present study demonstrates the tumorigenic effect of GHRH
in the human experimental tumour cell lines representative of
leading cancers. Our work supports the concept that GHRH
functions as growth factor in human cancers.
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